|
| 36191643 | Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. | J Affect Disord | 2023 |
| 37077711 | Targeting the Arginine Vasopressin V<sub>1b</sub> Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders. | Neuropsychiatr Dis Treat | 2023 |
| 37132201 | Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial. | Am J Psychiatry | 2023 |
| 36724109 | Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression. | J Clin Psychiatry | 2023 |
| 36811520 | Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. | J Clin Psychiatry | 2023 |
| 34352138 | A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults. | Hum Psychopharmacol | 2022 |
| 35378149 | Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder. | J Affect Disord | 2022 |
| 33387701 | Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study. | J Neurol Sci | 2021 |
| 33719782 | Achieving clinical response in postpartum depression leads to improvement in health-related quality of life. | Curr Med Res Opin | 2021 |
| 34154385 | Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids". | Am J Psychiatry | 2021 |
| 34190962 | Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. | JAMA Psychiatry | 2021 |
| 33181049 | Brexanolone in Postpartum Depression: <i>Post Hoc</i> Analyses to Help Inform Clinical Decision-Making. | J Womens Health (Larchmt) | 2021 |
| 31338688 | SAGE-217, A Novel GABA<sub>A</sub> Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies. | Clin Pharmacokinet | 2020 |
| 32666402 | Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression. | Arch Womens Ment Health | 2020 |
| 32435663 | Allopregnanolone in postpartum depression: Role in pathophysiology and treatment. | Neurobiol Stress | 2020 |
| 31255299 | Brexanolone injection for post-partum depression treatment - Authors' reply. | Lancet | 2019 |
| 31774969 | Trial of SAGE-217 in Patients with Major Depressive Disorder. Reply. | N Engl J Med | 2019 |
| 30177236 | Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. | Lancet | 2018 |
| 27556834 | Burden of illness for super-refractory status epilepticus patients. | J Med Econ | 2017 |
| 28370307 | Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. | Hum Psychopharmacol | 2017 |
| 28779545 | Brexanolone as adjunctive therapy in super-refractory status epilepticus. | Ann Neurol | 2017 |
| 28619476 | Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. | Lancet | 2017 |
| 26111262 | First Human Study of the Investigational Sedative and Anesthetic Drug AZD3043: A Dose-Escalation Trial to Assess the Safety, Pharmacokinetics, and Efficacy of a 30-Minute Infusion in Healthy Male Volunteers. | Anesth Analg | 2015 |
| 26097986 | A Bolus and Bolus Followed by Infusion Study of AZD3043, an Investigational Intravenous Drug for Sedation and Anesthesia: Safety and Pharmacodynamics in Healthy Male and Female Volunteers. | Anesth Analg | 2015 |
| 24525659 | The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study. | J Clin Psychopharmacol | 2014 |
| 25363147 | Pediatric super-refractory status epilepticus treated with allopregnanolone. | Ann Neurol | 2014 |
| 23430984 | A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers. | Cephalalgia | 2013 |
| 22391030 | Glutamate-based depression GBD. | Med Hypotheses | 2012 |
| 22955840 | Association of schizophrenia with the phenylthiocarbamide taste receptor haplotype on chromosome 7q. | Psychiatr Genet | 2012 |
| 19030002 | Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia. | Mol Psychiatry | 2009 |
| 18230676 | Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression. | Learn Mem | 2008 |
| 16738544 | Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. | Neuropsychopharmacology | 2007 |
| 17329469 | Visual attention circuitry in schizophrenia investigated with oddball event-related functional magnetic resonance imaging. | Am J Psychiatry | 2007 |
| 17475741 | Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. | Am J Psychiatry | 2007 |
| 17081698 | Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. | Neuroscience | 2007 |
| 17119931 | Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. | Psychopharmacology (Berl) | 2007 |
| 17208411 | Phenylthiocarbamide (PTC) perception in patients with schizophrenia and first-degree family members: relationship to clinical symptomatology and psychophysical olfactory performance. | Schizophr Res | 2007 |
| 16123740 | Corticosterone modulates auditory gating in mouse. | Neuropsychopharmacology | 2006 |
| 17050269 | Olfactory functioning in schizophrenia: relationship to clinical, neuropsychological, and volumetric MRI measures. | J Clin Exp Neuropsychol | 2006 |
| 16750890 | Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. | Neuroscience | 2006 |
| 16513864 | Prognostic variables at intake and long-term level of function in schizophrenia. | Am J Psychiatry | 2006 |
| 16192313 | Ketamine produces lasting disruptions in encoding of sensory stimuli. | J Pharmacol Exp Ther | 2006 |
| 15800154 | Phenylthiocarbamide perception in patients with schizophrenia and first-degree family members. | Am J Psychiatry | 2005 |
| 16199830 | Levels-of-processing effect on frontotemporal function in schizophrenia during word encoding and recognition. | Am J Psychiatry | 2005 |
| 15908134 | Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. | Neuroscience | 2005 |
| 15093687 | Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy. | Brain Res Mol Brain Res | 2004 |
| 15176475 | The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. | Neurochem Res | 2004 |
| 15489033 | Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. | Neuroscience | 2004 |
| 14970826 | Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine. | Neuropsychopharmacology | 2004 |
| 14735128 | Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. | Neuropsychopharmacology | 2004 |